Systematically characterizing and prioritizing chemosensitivity related gene based on Gene Ontology and protein interaction network

[1]  Xiao-dong Zhu,et al.  Identification of genes involved in radioresistance of nasopharyngeal carcinoma by integrating gene ontology and protein-protein interaction networks. , 2011, International journal of oncology.

[2]  Peng Wang,et al.  A novel method to quantify gene set functional association based on gene ontology , 2012, Journal of The Royal Society Interface.

[3]  Eric E. Bardes,et al.  Integrative systems biology approaches to identify and prioritize disease and drug candidate genes. , 2011, Methods in molecular biology.

[4]  C. Cobelli,et al.  The Transcriptional Response in Human Umbilical Vein Endothelial Cells Exposed to Insulin: A Dynamic Gene Expression Approach , 2010, PloS one.

[5]  Kou-Juey Wu,et al.  Regulation of Excision Repair Cross-Complementation Group 1 by Snail Contributes to Cisplatin Resistance in Head and Neck Cancer , 2010, Clinical Cancer Research.

[6]  Michele Purrello,et al.  Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy , 2010, BMC Cancer.

[7]  Yi Chen,et al.  Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer , 2010, Journal of Molecular Medicine.

[8]  V. Prassolov,et al.  Interactions of the p53 Protein Family in Cellular Stress Response in Gastrointestinal Tumors , 2010, Molecular Cancer Therapeutics.

[9]  Hans-Werner Mewes,et al.  CORUM: the comprehensive resource of mammalian protein complexes , 2007, Nucleic Acids Res..

[10]  F. Orso,et al.  Interference with Activator Protein-2 transcription factors leads to induction of apoptosis and an increase in chemo- and radiation-sensitivity in breast cancer cells , 2010, BMC Cancer.

[11]  Gabriele Sales,et al.  Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. , 2009, Blood.

[12]  Xin Zhou,et al.  Novel software package for cross-platform transcriptome analysis (CPTRA) , 2009, BMC Bioinformatics.

[13]  William C Reinhold,et al.  CellMiner: a relational database and query tool for the NCI-60 cancer cell lines , 2009, BMC Genomics.

[14]  Mauno Vihinen,et al.  Identification of candidate disease genes by integrating Gene Ontologies and protein-interaction networks: case study of primary immunodeficiencies , 2008, Nucleic acids research.

[15]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[16]  Rong Li,et al.  Decreased BRCA1 Confers Tamoxifen Resistance in Breast Cancer Cells by Altering Estrogen Receptor-Coregulator Interactions , 2008, Oncogene.

[17]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[18]  J. Weinstein,et al.  Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines , 2008, Molecular Cancer Therapeutics.

[19]  S. Fulda,et al.  Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells , 2008, Oncogene.

[20]  M. Broggini,et al.  Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil , 2008, Clinical Cancer Research.

[21]  Sven Bergmann,et al.  A modular approach for integrative analysis of large-scale gene-expression and drug-response data , 2008, Nature Biotechnology.

[22]  Octave Noubibou Doudieu,et al.  CORUM: the comprehensive resource of mammalian protein complexes , 2007, Nucleic Acids Res..

[23]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[24]  F. Rojo,et al.  Inhibition of the Canonical IKK/NFκB Pathway Sensitizes Human Cancer Cells to Doxorubicin , 2007 .

[25]  Mario Medvedovic,et al.  Bayesian hierarchical model for transcriptional module discovery by jointly modeling gene expression and ChIP-chip data , 2007, BMC Bioinformatics.

[26]  F. Shepherd,et al.  Weighing Tumor Biology in Treatment Decisions for Patients with Non-small Cell Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  Ruiwen Wang,et al.  Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates , 2007, Molecular Cancer Therapeutics.

[28]  K. Tao,et al.  Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells. , 2007, The Journal of surgical research.

[29]  Jae K. Lee,et al.  Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study , 2007, Molecular Cancer Therapeutics.

[30]  Ying Huang.  Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy , 2007, Cancer and Metastasis Reviews.

[31]  F. Rojo,et al.  Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. , 2007, Cell cycle.

[32]  R. Shoemaker.  The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[33]  Zhenyu Ding,et al.  Predicting Cancer Drug Response by Proteomic Profiling , 2006, Clinical Cancer Research.

[34]  William C Reinhold,et al.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel , 2006, Molecular Cancer Therapeutics.

[35]  William E. Evans,et al.  Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy , 2006, Nature Reviews Cancer.

[36]  Gábor Csárdi,et al.  The igraph software package for complex network research , 2006 .

[37]  Sangsoo Kim,et al.  Gene expression Differential coexpression analysis using microarray data and its application to human cancer , 2005 .

[38]  M. Qiao,et al.  Activation of STAT3 signaling in human stomach adenocarcinoma drug-resistant cell line and its relationship with expression of vascular endothelial growth factor. , 2005, World journal of gastroenterology.

[39]  K. Blackwell,et al.  The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. , 2005, Cancer research.

[40]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[41]  T. Jacks,et al.  Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents , 2004, Oncogene.

[42]  Feng Gao,et al.  Defining transcriptional networks through integrative modeling of mRNA expression and transcription factor binding data , 2004, BMC Bioinformatics.

[43]  Andrew J. Wilson,et al.  Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. , 2003, Cancer research.

[44]  William C Reinhold,et al.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  V. Ewerbeck,et al.  Identification of drug‐regulated genes in osteosarcoma cells , 2003, International journal of cancer.

[46]  C. Bokemeyer,et al.  Molecular determinants of treatment response in human germ cell tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  Yusuke Nakamura,et al.  An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. , 2002, Cancer research.

[48]  J. Weinstein,et al.  Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data , 2002, The Pharmacogenomics Journal.

[49]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[51]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[52]  H. Westerhoff,et al.  In vitro transepithelial drug transport by on-line measurement: cellular control of paracellular and transcellular transport. , 1999, Journal of Pharmacy and Science.

[53]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[54]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[55]  G. Dickneite,et al.  First-pass elimination of a peptidomimetic thrombin inhibitor is due to carrier-mediated uptake by the liver. Interaction with bile acid transport systems. , 1996, Biochemical pharmacology.

[56]  G. Evan,et al.  Oncogenes and cell death. , 1994, Current opinion in genetics & development.

[57]  D A Scudiero,et al.  Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. , 1989, Journal of the National Cancer Institute.